SRC and glioblastoma: As the cancer clinics move towards personalized treatments, and once EGFRvIII mutation can be detected in cerebrospinal fluid through liquid biopsy11, non-toxic Src inhibition can be further explored as a strategy to enhance the success of surgical removal of GBM tumors harboring EGFRvIII mutation.